Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

References

• Willemze R, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354–371
   PubMed Web of Science ®Google Scholar
• Willemze R, Meijer C J. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. European Organization for Research and Treatment of Cancer. Am J Dermatopathol 1999; 21: 265–273
   PubMed Web of Science ®Google Scholar
• Harris N L, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Willemze R, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter J A, Press O W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673–683
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter J A, Press O W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–1652
   PubMed Web of Science ®Google Scholar
• Golay J, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634–641
   PubMed Web of Science ®Google Scholar
• Davis T A, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–1857
   PubMed Web of Science ®Google Scholar
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
   PubMed Web of Science ®Google Scholar
• Coiffier B, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932
   PubMed Web of Science ®Google Scholar
• Czuczman M S, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Czuczman M S, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Vose J M, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
   PubMed Web of Science ®Google Scholar
• Feugier P, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Smith B D, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634–639
   PubMed Web of Science ®Google Scholar
• Kirova Y M, Piedbois Y, Le Bourgeois J P. Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases. Radiother Oncol 1999; 52: 15–18
   PubMed Web of Science ®Google Scholar
• Sah A, et al. Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol 2004; 75: 195–199
   PubMed Web of Science ®Google Scholar
• Piccinno R, et al. Radiotherapy of cutaneous B cell lymphomas: our experience in 31 cases. Int J Radiat Oncol Biol Phys 1993; 27: 385–389
   PubMed Web of Science ®Google Scholar
• Ingen-Housz-Oro S, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant 2004; 33: 629–634
   PubMed Web of Science ®Google Scholar
• Gellrich S, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas – an applicational observation. Br J Dermatol 2005; 153: 167–173
   PubMed Web of Science ®Google Scholar
• Heinzerling L, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136: 374–378
   PubMed Web of Science ®Google Scholar
• Soda R, et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001; 81: 207–208
   PubMed Web of Science ®Google Scholar
• Viguier M, et al. Cutaneous B-cell lymphoma treatment with rituximab: two cases. Ann Dermatol Venereol 2002; 129: 1152–1155
   PubMed Web of Science ®Google Scholar
• Sabroe R A, et al. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br J Dermatol 2000; 143: 157–161
   PubMed Web of Science ®Google Scholar
• Paul T, et al. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 1239–1243
   PubMed Web of Science ®Google Scholar
• Heinzerling L M, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835–1844
   PubMed Web of Science ®Google Scholar
• Fink-Puches R, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005; 52: 847–853
   PubMed Web of Science ®Google Scholar
• Aboulafia D M. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol 2001; 24: 237–240
   PubMed Web of Science ®Google Scholar
• Brogan B L, et al. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series. J Am Acad Dermatol 2003; 49: 223–228
   PubMed Web of Science ®Google Scholar
• Gellrich S, et al. Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients. Hautarzt 2001; 52: 205–210
   PubMed Web of Science ®Google Scholar
• Shapiro M, et al. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol 2002; 47: 623–628
   PubMed Web of Science ®Google Scholar
• Ghielmini M, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004; 103: 4416–4423
   PubMed Web of Science ®Google Scholar
• Hainsworth J D. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004; 31(1 Suppl 2)17–21
   PubMed Web of Science ®Google Scholar
• Fierro M T, et al. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. J Am Acad Dermatol 2003; 49: 281–287
   PubMed Web of Science ®Google Scholar
• Grange F, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood 2004; 103: 3662–3668
   PubMed Web of Science ®Google Scholar
• Grange F, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602–3610
   PubMed Web of Science ®Google Scholar
• Mounier N, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large-B-cell lymphoma (CLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Colombat P, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar
• Aguilera N S, et al. Cutaneous follicle center lymphoma: a clinicopathologic study of 19 cases. Modern Pathol 2001; 14: 828–835
   PubMed Web of Science ®Google Scholar
• Bergman R, et al. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol 2001; 137: 432–439
   PubMed Web of Science ®Google Scholar
• Mirza I, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 2002; 20: 647–655
   PubMed Web of Science ®Google Scholar
• Leinweber B, et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol 2004; 26: 4–13
   PubMed Web of Science ®Google Scholar
• Cerroni L, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000; 95: 3922–3928
   PubMed Web of Science ®Google Scholar
• Hoefnagel J J, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105: 3671–3678
   PubMed Web of Science ®Google Scholar
• Giannotti B, Santucci M. Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity. Arch Dermatol 1993; 129: 353–355
   PubMed Web of Science ®Google Scholar
• Pimpinelli N, Santucci M, Giannotti B. Cutaneous lymphoma: a clinically relevant classification. Int J Dermatol 1993; 32: 695–700
   PubMed Web of Science ®Google Scholar
• Hallermann C, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 123: 213–219
   PubMed Web of Science ®Google Scholar
• Hallermann C, et al. Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. J Invest Dermatol 2004; 122: 1495–1502
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165: 3797–3803
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Linking innate and adaptive immunity. Nature Med 1999; 5: 868–870
   PubMed Web of Science ®Google Scholar
• Liu Y J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106: 259–262
   PubMed Web of Science ®Google Scholar
• Selenko N, et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies. J Clin Immunol 2002; 22: 124–130
   PubMed Web of Science ®Google Scholar
• Selenko N, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15: 1619–1626
   PubMed Web of Science ®Google Scholar
• Ratzinger G, et al. Mature human Langerhans cells derived from CD34 + hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 2004; 173: 2780–2781
   PubMed Web of Science ®Google Scholar
• Banchereau J, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–6458
   PubMed Web of Science ®Google Scholar